当前位置: 首页 >> 检索结果
4841. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
作者: Stacie M Jones.;Edwin H Kim.;Kari C Nadeau.;Anna Nowak-Wegrzyn.;Robert A Wood.;Hugh A Sampson.;Amy M Scurlock.;Sharon Chinthrajah.;Julie Wang.;Robert D Pesek.;Sayantani B Sindher.;Mike Kulis.;Jacqueline Johnson.;Katharine Spain.;Denise C Babineau.;Hyunsook Chin.;Joy Laurienzo-Panza.;Rachel Yan.;David Larson.;Tielin Qin.;Don Whitehouse.;Michelle L Sever.;Srinath Sanda.;Marshall Plaut.;Lisa M Wheatley.;A Wesley Burks.; .
来源: Lancet. 2022年399卷10322期359-371页
For young children with peanut allergy, dietary avoidance is the current standard of care. We aimed to assess whether peanut oral immunotherapy can induce desensitisation (an increased allergic reaction threshold while on therapy) or remission (a state of non-responsiveness after discontinuation of immunotherapy) in this population.
4845. Intersectionality and developing evidence-based policy.
作者: Irtiza Qureshi.;Mayuri Gogoi.;Amani Al-Oraibi.;Fatimah Wobi.;Daniel Pan.;Christopher A Martin.;Jonathan Chaloner.;Katherine Woolf.;Manish Pareek.;Laura B Nellums.
来源: Lancet. 2022年399卷10322期355-356页 4856. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
作者: Lulu Bravo.;Igor Smolenov.;Htay Htay Han.;Ping Li.;Romana Hosain.;Frank Rockhold.;Sue Ann Costa Clemens.;Camilo Roa.;Charissa Borja-Tabora.;Antoinette Quinsaat.;Pio Lopez.;Eduardo López-Medina.;Leonardo Brochado.;Eder A Hernández.;Humberto Reynales.;Tatiana Medina.;Hector Velasquez.;Leonardo Bautista Toloza.;Edith Johana Rodriguez.;Dora Ines Molina de Salazar.;Camilo A Rodríguez.;Eduardo Sprinz.;José Cerbino-Neto.;Kleber Giovanni Luz.;Alexandre Vargas Schwarzbold.;Maria Sanali Paiva.;Josefina Carlos.;May Emmeline B Montellano.;Mari Rose A de Los Reyes.;Charles Y Yu.;Edison R Alberto.;Mario M Panaligan.;Milagros Salvani-Bautista.;Erik Buntinx.;Maya Hites.;Jean-Benoit Martinot.;Qasim E Bhorat.;Aysha Badat.;Carmen Baccarini.;Branda Hu.;Jaco Jurgens.;Jan Engelbrecht.;Donna Ambrosino.;Peter Richmond.;George Siber.;Joshua Liang.;Ralf Clemens.
来源: Lancet. 2022年399卷10323期461-472页
A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccine SCB-2019.
4858. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
作者: Edward J Carr.;Mary Wu.;Ruth Harvey.;Roseanne E Billany.;Emma C Wall.;Gavin Kelly.; .;Michael Howell.;George Kassiotis.;Charles Swanton.;Sonia Gandhi.;David Lv Bauer.;Matthew Pm Graham-Brown.;Rachel B Jones.;Rona M Smith.;Stephen McAdoo.;Michelle Willicombe.;Rupert Beale.
来源: Lancet. 2022年399卷10327期800-802页 4859. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Antimicrobial resistance (AMR) poses a major threat to human health around the world. Previous publications have estimated the effect of AMR on incidence, deaths, hospital length of stay, and health-care costs for specific pathogen-drug combinations in select locations. To our knowledge, this study presents the most comprehensive estimates of AMR burden to date.
|